US Patent No: 8,226,945
Number of patents in Portfolio can not be more than 2000
Antibodies and immunoconjugates and uses therefor
Stats
-
Jul 24, 2012
Issued date -
Nov 4, 2010
filing date -
12/939,533
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 4,970,198 Antitumor antibiotics (LL-E33288 complex) | 12 | 1987 | |
| 5,079,233 N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same | 9 | 1989 | |
| 5,606,040 Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group | 7 | 1993 | |
| 5,773,001 Conjugates of methyltrithio antitumor agents and intermediates for their synthesis | 43 | 1994 | |
| 5,739,116 Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents | 19 | 1995 | |
| 5,767,285 Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents | 15 | 1995 | |
|
|
|||
| 6,194,551 Polypeptide variants | 117 | 1999 | |
| 2004/0001,827 Serum albumin binding peptides for tumor targeting | 6 | 2002 | |
| 2005/0238,650 Compositions and methods for the treatment of tumor of hematopoietic origin | 20 | 2004 | |
| 2005/0276,812 Antibody-drug conjugates and methods | 20 | 2005 | |
| 2008/0050,310 ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | 5 | 2007 | |
|
|
|||
| 5,208,020 Cytotoxic agents comprising maytansinoids and their therapeutic use | 98 | 1992 | |
| 5,416,064 Cytotoxic agents comprising maytansinoids and their therapeutic use | 69 | 1992 | |
| 6,441,163 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents | 47 | 2001 | |
| 2005/0169,933 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates | 16 | 2004 | |
|
|
|||
| 5,585,089 Humanized immunoglobulins | 608 | 1995 | |
| 5,693,762 Humanized immunoglobulins | 468 | 1995 | |
|
|
|||
| 2004/0018,194 Recombinant anti-CD30 antibodies and uses thereof | 30 | 2003 | |
| 2005/0238,649 Monomethylvaline compounds capable of conjugation to ligands | 32 | 2004 | |
|
|
|||
| 5,767,237 Peptide derivatives | 26 | 1996 | |
| 6,124,431 Peptide derivatives | 22 | 1998 | |
|
|
|||
| 7,084,257 Fully human antibody Fab fragments with human interferon-gamma neutralizing activity | 27 | 2001 | |
|
|
|||
| 4,975,278 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells | 177 | 1988 | |
|
|
|||
| 5,789,554 Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells | 46 | 1996 | |
|
|
|||
| 2005/0244,828 Elisa assay of serum soluble cd22 to assess tumor burnden/relapse in subjects with leukemia and lymphoma | 2 | 2004 | |
|
|
|||
| 2009/0053,226 Compositions and methods for the treatment of tumor of hematopoietic origin | 3 | 2008 | |
| 2011/0045,005 COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN | 3 | 2010 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Jan 24, 2016 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jan 24, 2020 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jan 24, 2024 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |